Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T15:02:46.458Z.
Calculation as of: 2026-10-06T15:02:46.458Z.
Quote observation: 2026-10-06T15:00:29.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8ce36116f6c4cf8d6fa5d70ec9ce1d9cbc86489a03ebd5e18b87b9f8ced35068
EARNINGS YIELD
N/A
Market Cap
$1.46B
Earnings Yield
8.02%
TTM Avg
4.29%
3Y Avg
4.28%
5Y Avg
3.97%
Market Cap
$1.51B
Earnings Yield
0.70%
TTM Avg
0.66%
3Y Avg
1.46%
5Y Avg
1.46%
Market Cap
$1.52B
Earnings Yield
11.47%
TTM Avg
11.16%
3Y Avg
11.07%
5Y Avg
8.79%
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GH Research PLC (GHRS) | $1.47B | N/A | N/A | N/A | N/A |
| Certara, Inc. (CERT)vs › | $1.48B | N/A | 0.64% | 0.61% | 0.61% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 8.02% | 4.29% | 4.28% | 3.97% |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | N/A | N/A | N/A | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.45B | N/A | N/A | N/A | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.44B | 11.06% | 10.64% | 10.64% | 2.45% |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.51B | 0.70% | 0.66% | 1.46% | 1.46% |
| Nutex Health, Inc. (NUTX)vs › | $1.52B | 11.47% | 11.16% | 11.07% | 8.79% |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.41B | N/A | N/A | N/A | N/A |
| Innoviva, Inc. (INVA)vs › | $1.54B | 19.67% | 14.67% | 9.72% | 12.69% |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
